Functional mutant of human plasminogen, its preparation method and application

A technology of human plasminogen and plasminogen, applied in botany equipment and methods, biochemical equipment and methods, applications, etc., can solve the PLM mutation that has not yet had both thrombolytic, anticoagulant and antithrombotic effects Body and other problems, to achieve the effects of refolding, reducing pro-inflammatory side effects, and increasing the possibility
CN102199587AInactive Publication Date: 2011-09-28GUANGDONG PHARMA UNIV
2 Cites 16 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
GUANGDONG PHARMA UNIV
Publication Date
2011-09-28
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A functional mutant of human plasminogen disclosed in the invention, respectively, is hPLG-delta K: human plasminogen protein Pro<544>-Asn<791> polypeptide; Pro<559> in RGD-hPLG-delta K: hPLG-delta K is mutated to Asp<559>; and Gly<560> in RHP-hPLG-delta K: hPLG-delta K polypeptide is mutated to His<560>. The invention also discloses a preparation method for the functional mutant. The product is obtained by using a plasmid containing a full-length cDNA sequence of human plasminogen as a template to carry out a PCR to construct a plasmid and using Pichia Pastoris expression. The functional mutant has a dual-function of fibrinolysis and inhibiting platelet aggregation or inhibiting fibrin monomer polymerization.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of biotechnology and pharmaceuticals, in particular to a functional mutant of human plasminogen and a preparation method and application thereof. Background technique

[0002] Embolism is one of the important causes of death from cardiovascular and cerebrovascular diseases, and thrombolytic therapy is an effective means. The main thrombolytic drugs currently used clinically, such as tissue plasminogen activator (Tissue-type plasminogen activator, t-PA), urokinase (Urokinase-type plasminogen activator, UK), streptokinase (Streptokinase, SK), etc., Although it shows a certain therapeutic effect, it can only exert thrombolytic effect after activating plasminogen (PLG) in the blood to plasmin (PLM), so the efficiency for old thrombus is low, resulting in a treatment time window. Short, high bleeding complications and other shortcomings. And because there is no antithrombotic function, it is easy to occur the situation o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More